Blockchain Registration Transaction Record

Sigyn Therapy Study Targets Cardiovascular Death Reduction in Dialysis Patients

Sigyn Therapeutics announces clinical study of Sigyn Therapy to reduce cardiovascular events in dialysis patients. Technology targets inflammation and cholesterol simultaneously on existing equipment.

This development matters because cardiovascular disease remains the leading cause of death globally and is particularly devastating for end-stage renal disease patients undergoing dialysis. Current lipoprotein apheresis treatments, while effective, are severely limited to specialized centers, leaving most patients without access. Sigyn Therapy's potential to be deployed on existing dialysis equipment could democratize life-extending treatment for hundreds of thousands of high-risk patients while addressing the $34 billion dialysis industry's fundamental challenge of cardiovascular mortality. Successful implementation could transform standard care protocols and significantly improve survival rates for one of medicine's most vulnerable patient populations.